Sedia Biosciences Corp.

Sedia Biosciences Corp. is a biotechnology startup based in Portland, Oregon, founded in 2009. The company focuses on advancing access to care through innovation, particularly in three key areas: rapid point of care diagnostic assays, novel HIV epidemiological disease incidence assays, and remote clinical specimen collection devices. Sedia Biosciences has received a $1.80M grant investment from the National Institutes of Health in August 30, 2016. This funding serves as a testament to the company's potential and the significance of its work in the medical device and diagnostics space. The startup brings together a dedicated team of researchers, scientists, and business professionals with the common mission of developing, manufacturing, and licensing innovative technologies and products to improve global access to medical care. Sedia Biosciences' dedication to addressing the global access to care challenges through advancements in diagnostic tools and specimen collection devices positions it as a promising player in the biotechnology industry. With its emphasis on addressing critical public health needs, the company presents an intriguing opportunity for investors seeking impactful ventures in the healthcare space.